Publicaciones en colaboración con investigadores/as de Hospital de Gran Canaria Dr. Negrin (16)

2023

  1. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

2022

  1. Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 5, pp. 994-999

2021

  1. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

    Neurologia, Vol. 36, Núm. 8, pp. 611-617

2019

  1. High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients

    BMC neurology, Vol. 19, Núm. 1, pp. 167

  2. Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients

    Journal of Critical Care, Vol. 51, pp. 117-121

2015

  1. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity

    Journal of Thrombosis and Haemostasis, Vol. 13, Núm. 7, pp. 1274-1278

  2. Common variants of NFE2L2 gene predisposes to acute respiratory distress syndrome in patients with severe sepsis

    Critical Care, Vol. 19, Núm. 1

  3. Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction

    BMC Neurology, Vol. 15, Núm. 1

2014

  1. Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury

    PLoS ONE, Vol. 9, Núm. 4

  2. Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio

    PLoS ONE, Vol. 9, Núm. 4

  3. Clinical management guidelines for subarachnoid haemorrhage. Diagnosis and treatment

    Neurologia

  4. Sustained high plasma plasminogen activator inhibitor-1 levels are associated with severity and mortality in septic patients

    Thrombosis Research, Vol. 134, Núm. 1, pp. 182-186

2013

  1. The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis

    Critical Care, Vol. 17, Núm. 3

2011

  1. Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis

    Critical Care, Vol. 15, Núm. 2

2010

  1. Matrix metalloproteinases and their inhibitors as biomarkers of severity in sepsis

    Critical Care

2009

  1. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis

    Critical Care, Vol. 13, Núm. 5